WO2012053827A3 - Ｃｘｃｒ２에 결합하는 펩타이드 리간드를 포함하는 감염성 및 염증성 질환 치료용 조성물 - Google Patents

Ｃｘｃｒ２에 결합하는 펩타이드 리간드를 포함하는 감염성 및 염증성 질환 치료용 조성물 Download PDF

Info

Publication number
WO2012053827A3
WO2012053827A3 PCT/KR2011/007807 KR2011007807W WO2012053827A3 WO 2012053827 A3 WO2012053827 A3 WO 2012053827A3 KR 2011007807 W KR2011007807 W KR 2011007807W WO 2012053827 A3 WO2012053827 A3 WO 2012053827A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory diseases
cxcr2
infective
peptide ligand
composition containing
Prior art date
Application number
PCT/KR2011/007807
Other languages
English (en)
French (fr)
Other versions
WO2012053827A2 (ko
WO2012053827A9 (ko
Inventor
배외식
김상두
Original Assignee
성균관대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성균관대학교산학협력단 filed Critical 성균관대학교산학협력단
Priority to US13/880,889 priority Critical patent/US8937038B2/en
Publication of WO2012053827A2 publication Critical patent/WO2012053827A2/ko
Publication of WO2012053827A9 publication Critical patent/WO2012053827A9/ko
Publication of WO2012053827A3 publication Critical patent/WO2012053827A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 감염성 및 염증성 질환 치료제에 관한 것으로, 보다 자세하게는 CXCR2에 결합하는 펩타이드 리간드, 특히 Ac-PGP를 유효성분으로 포함하는 감염성 및 염증성 질환 치료용 약학 조성물에 관한 것이다. 본 발명의 유효성분은 식세포에 의한 박테리아의 제거를 촉진하고, 염증을 억제하며, 면역세포의 아폽토시스를 억제하여 패혈증 및 패혈증 쇼크를 포함한 감염성 및 염증성 질환을 예방 및 치료할 수 있다.
PCT/KR2011/007807 2010-10-22 2011-10-19 Ｃｘｃｒ２에 결합하는 펩타이드 리간드를 포함하는 감염성 및 염증성 질환 치료용 조성물 WO2012053827A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/880,889 US8937038B2 (en) 2010-10-22 2011-10-19 Composition containing peptide ligand that bonds with CXCR2 for treating infective and inflammatory diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100103259A KR101247641B1 (ko) 2010-10-22 2010-10-22 Ｃｘｃｒ２에 결합하는 펩타이드 리간드를 포함하는 감염성 및 염증성 질환 치료용 조성물
KR10-2010-0103259 2010-10-22

Publications (3)

Publication Number Publication Date
WO2012053827A2 WO2012053827A2 (ko) 2012-04-26
WO2012053827A9 WO2012053827A9 (ko) 2012-07-05
WO2012053827A3 true WO2012053827A3 (ko) 2012-08-23

Family

ID=45975733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/007807 WO2012053827A2 (ko) 2010-10-22 2011-10-19 Ｃｘｃｒ２에 결합하는 펩타이드 리간드를 포함하는 감염성 및 염증성 질환 치료용 조성물

Country Status (3)

Country Link
US (1) US8937038B2 (ko)
KR (1) KR101247641B1 (ko)
WO (1) WO2012053827A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501133A (ja) * 2013-11-25 2017-01-12 エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ Ｃｘｃｒ拮抗性ペプチド及びその用途
WO2017217728A1 (ko) * 2016-06-13 2017-12-21 부산대학교 산학협력단 Ac-pgp 펩타이드를 유효성분으로 포함하는 혈관 신생 촉진용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077705A1 (en) * 2001-03-01 2003-04-24 Gordon John R. High-affinity antagonists of ELR-CXC chemokines
US20040208873A1 (en) * 2002-12-16 2004-10-21 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366678A1 (en) 1999-03-09 2000-09-14 Fornix Biosciences N.V. Synthetic complementary peptides and ophthalmologic uses thereof
WO2005103702A2 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077705A1 (en) * 2001-03-01 2003-04-24 Gordon John R. High-affinity antagonists of ELR-CXC chemokines
US20040208873A1 (en) * 2002-12-16 2004-10-21 Medarex, Inc. Human monoclonal antibodies against interleukin 8 (IL-8)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NATHANIAL M. WEATHINGTON ET AL.: "A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation", NATURE MEDICINE, vol. 12, no. 3, March 2006 (2006-03-01), pages 317 - 323 *
PETRA DE KRUIJF ET AL.: "The collagen-breakdown product N-acetyl-Proline- Glycine-Proline (n-alpha-PGP) does not interact directly with human CXCR1 and CXCR2", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 643, 21 June 2010 (2010-06-21), pages 29 - 33 *

Also Published As

Publication number Publication date
US8937038B2 (en) 2015-01-20
WO2012053827A2 (ko) 2012-04-26
US20130252878A1 (en) 2013-09-26
KR101247641B1 (ko) 2013-03-29
KR20120041875A (ko) 2012-05-03
WO2012053827A9 (ko) 2012-07-05

Similar Documents

Publication Publication Date Title
WO2012106281A3 (en) Multimodal trail molecules and uses in cellular therapies
WO2013078170A8 (en) Purification of anti-c-met antibodies
WO2013066835A3 (en) Compounds and methods
WO2013066839A3 (en) Compounds and methods
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
EA201391315A1 (ru) Гуанидиновое соединение
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
WO2011113019A3 (en) Ctla4 proteins and their uses
EP3470526A3 (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
WO2012135032A3 (en) Anti-inflammatory particles
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
WO2012092458A3 (en) Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
WO2011041399A3 (en) Pi3k (delta) selective inhibitors
WO2012104007A3 (de) 7-azaindolderivate
WO2012129341A3 (en) Disease detection in plants
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
EP2377542A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF BONE DISEASE OR TO PREVENT INFLAMMATION, COMPRISING CARTILAGE STEM CELLS AS AN ACTIVE PRINCIPLE
WO2012050611A3 (en) Aptamers to glycoprotein vi
TR201009167A2 (tr) Sefalosporin içeren farmasötik granüller.
WO2011067209A3 (en) Pesticidal mixtures

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11834627

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13880889

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11834627

Country of ref document: EP

Kind code of ref document: A2